Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.

Blood Adv · 2023 · PMC10463194 · PMID 37067952

Europe PMC DOI

hedged sentence

0.3600

closest p · 7.2× alpha

0.3600

boldest claim

The sentences

did not reach statistical significanceP = .36not close (p > 0.1)

Overall response and CR rates were 42.0% (95% confidence interval [CI], 31.6-53.1) and 23.9% (95% CI, 15.4-34.1), respectively; CR rate did not reach statistical significance vs the historical control ( P = .36).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.